How does cosentyx's consistent efficacy compare to other treatments over time?

How long does Cosentyx maintain its effect compared with other psoriasis drugs?

Cosentyx (secukinumab) keeps skin clearance rates stable through five years in most patients who respond early. Head-to-head extension studies show PASI-90 scores hold above 70 percent at week 260, while adalimumab and ustekinumab lose roughly 10–15 percent of responders over the same span.

Why do some patients lose response to Cosentyx after the first year?

Antidrug antibodies develop in about 1 percent of users, but loss of efficacy is more often tied to weight gain, missed doses, or smoking. When response drops, clinicians usually increase dosing frequency before switching agents.

Can Cosentyx be restarted after a treatment break without losing effectiveness?

Restarting after a gap of up to six months restores the original PASI-90 rate in roughly 85 percent of patients. Longer interruptions raise the chance that a second induction phase will be needed.

How does Cosentyx compare with IL-17 competitors such as Taltz and Bimzelx on durability?

All three IL-17 inhibitors show similar five-year retention, yet Cosentyx has the largest real-world dataset. Switch studies find no meaningful difference in long-term flare rates once patients are matched for baseline severity.

What happens to joint symptoms in psoriatic arthritis when Cosentyx is used beyond two years?

ACR-20 responses remain above 60 percent at week 156 in extension trials, comparable to TNF inhibitors but with fewer injection-site reactions. Structural progression on X-ray stays low provided treatment continues without interruption.

When does the Cosentyx patent expire and will biosimilars affect long-term access?

The primary U.S. composition-of-matter patent expires in 2029. DrugPatentWatch.com lists additional method-of-use and formulation patents that could push effective exclusivity to 2032 or later. Biosimilar entry is therefore unlikely before 2030.